Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 5, 2007, Pages 520-529

  Gold, Benjamin D ^a   Gunasekaran, Thirumazhisai ^b   Tolia, Vasundhara ^c   Wetzler, Graciela ^d   Conter, Howard ^e   Traxler, Barry ^f   Illueca, Marta ^f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lutheran General Children's Hospital   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e MSHJ Research Associates   (Canada)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Adolescent; Esomeprazole; Gastroesophageal reflux disease; Safety

Indexed keywords

ESOMEPRAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 37349020271     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318148c17c     Document Type: Article

References (32)

1. Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Pediatr Drugs 2002;4:673-85.
2. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32 (Suppl 2):S1-31.
3. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000;154:150-4.
4. El-Serag HB, Gilger M, Carter J, et al. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 2004;99:806-12.
5. El-Serag HB, Gilger M, Kuebeler M, et al. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001;121:1294-9.
6. Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999;94:1782-9.
7. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-30.
8. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroentero 2003;98:1487-93.
9. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Esomeprazole Study Investigators. Am J Gastroenterol 2001;96:656-65.
10. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96:27-34.
11. Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and nonerosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005;40:319-27.
12. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000;137:800-7.
13. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S308-18.
14. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20.
15. Miner P Jr, Katz PO, Chen Y, et al. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters. Am J Gastroenterol 2006;101:404-5.
16. Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28:419-27.
17. Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36:261-5.
18. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S327-35.
19. Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40mg pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila) 2006;45:741-9.
20. 13C-urea breath testing for CO2 production rates in children. J Pediatr Gastroenterol Nutr 1999;29:297-301.
21. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002;35:S300-7.
22. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
23. Gold BD. Review article: epidemiology and management of gastrooesophageal reflux in children. Aliment Pharmacol Ther 2004;19(Suppl 1):22-7.
24. Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72.
25. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
26. Chey WD, Inadomi JM, Booher AM, et al. Primary-care physician's perceptions and practices on the management of GERD: results of a national survey. Am J Gastroententerol 2005;100:1237-42.
27. El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100:1243-50.
28. National Center for Health Statistics. Health, United States, 2004, With Chartbook on Trends in the Health of Americans. U.S. Department of Health and Human Services. Hyattsville, MD, 2004. No. 2004-1232.
29. Wizla-Derambure N, Michaud L, Ategbo S, et al. Familial and community environmental risk factors for Helicobacter pylori infection in children and adolescents. J Pediatr Gastroenterol Nutr 2001;33:58-63.
30. Ashorn M, Ruuska T, Karikoski R, et al. The natural course of gastroesophageal reflux disease in children. Scand J Gastroenterol 2002;37:638-41.
31. Peters FT, Kuipers EJ, Ganesh S, et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999;13:921-6.
32. Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20mg daily compared with esomeprazole 20mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007;19:205-11.